Glycoprotein A34, a novel target for antibody-based cancer immunotherapy

Cancer Immunity

Volumn 6, Issue , 2006, Pages

  Scanlan, Matthew J ^a   Ritter, Gerd ^a   Yin, Beatrice W T ^a   Williams Jr , Clarence ^a   Cohen, Leonard S ^a   Coplan, Keren A ^a   Fortunato, Sheila R ^a   Frosina, Denise ^a   Lee, Sang Yull ^a   Murray, Anne E ^a   Chua, Ramon ^a   Filonenko, Valeriy V ^b   Sato, Eiichi ^a   Old, Lloyd J ^a   Jungbluth, Achim A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

A34; Amino acid sequence homology; Human; Immunohistochemistry; Membrane glycoproteins; mRNA; Tissue distribution

Indexed keywords

A34 PROTEIN, HUMAN; ANTIBODY; CANCER ANTIBODY; CELL ADHESION MOLECULE; CELL SURFACE PROTEIN; COMPLEMENTARY DNA; DRUG THERAPY; GLYCOPROTEIN A33; GLYCOPROTEIN A34; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; BIOCHEMISTRY; BIOSYNTHESIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL STRAIN COS7; COLON CANCER; CONTROLLED STUDY; DATA BASE; DRUG TARGETING; ESOPHAGUS CARCINOMA; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; GENETICS; GERM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG CANCER; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH; STOMACH CANCER; STOMACH MUCOSA; TESTIS; THERAPY; TUMOR CELL;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; BIOSYNTHESIS; GENETICS; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; METABOLISM; MOLECULAR SEQUENCE DATA; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THERAPEUTIC USE; THERAPY;

EID: 30844469066     PISSN: 14249634     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29. (PMID: 11905803)
2. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52: 125-45. (PMID: 11160771)
3. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr., Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as firstline therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-95. (PMID: 12885806)
4. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746-51. (PMID: 12721250)
5. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-73. (PMID: 12130484)
6. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8. (PMID: 14993230)
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5. (PMID: 12506171)
8. Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 1996; 9: 465-71.
9. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1997; 94: 469-74. (PMID: 9012807)
10. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61: 6851-9. (PMID: 11559561)
11. Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003; 9: 1338-46. (PMID: 12684402)
12. Welt S, Ritter G, Williams C Jr, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003; 9: 1347-53. (PMID: 12684403)
13. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 2003; 15: 525-30. (PMID: 14519386)
14. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3. (PMID: 9036860)
15. Raschperger E, Engstrom U, Pettersson RF, Fuxe J. CLMP, a novel member of the CTX family and a new component of epithelial tight junctions. J Biol Chem 2004; 279: 796-804. (PMID: 14573622)
16. Chretien I, Marcuz A, Courtet M, Katevuo K, Vainio O, Heath JK, White SJ, Du Pasquier L. CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol 1998; 28: 4094-104. (PMID: 9862345)
17. Sobocka MB, Sobocki T, Banerjee P, Weiss C, Rushbrook JI, Norin AJ, Hartwig J, Salifu MO, Markell MS, Babinska A, Ehrlich YH, Kornecki E. Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation. Blood 2000; 95: 2600-9. (PMID: 10753840)
18. Cunningham SA, Arrate MP, Rodriguez JM, Bjercke RJ, Vanderslice P, Morris AP, Brock TA. A novel protein with homology to the junctional adhesion molecule. Characterization of leukocyte interactions. J Biol Chem 2000; 275: 34750-6. (PMID: 10945976)
19. Arrate MP, Rodriguez JM, Tran TM, Brock TA, Cunningham SA. Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor. J Biol Chem 2001; 276: 45826-32. (PMID: 11590146)
20. Hirata Ki, Ishida T, Penta K, Rezaee M, Yang E, Wohlgemuth J, Quertermous T. Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells. J Biol Chem 2001; 276: 16223-31. (PMID: 11279107)
21. Suzu S, Hayashi Y, Harumi T, Nomaguchi K, Yamada M, Hayasawa H, Motoyoshi K. Molecular cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and testis. Biochem Biophys Res Commun 2002; 296: 1215-21. (PMID: 12207903)
22. NCBI BLAST, Protein query vs. translated database (tblastn). URL: http://www.ncbi.nlm.nih.gov/BLAST/
23. SOSUI WWW Server: Classification and Secondary Structure Prediction of Membrane Proteins. URL: http://sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html
24. TMHMM Server v. 2.0 (prediction of transmembrane helices in proteins). URL: http://www.cbs.dtu.dk/services/TMHMM/
25. The Eukaryote Linear Motif resource for Functional Sites in Proteins. URL: http://elm.eu.org
26. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organspecific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 2000; 46 Suppl: S27-32. (PMID: 10950144)
27. Katoh M, Katoh M. IGSF11 gene, frequently up-regulated in intestinal-type gastric cancer, encodes adhesion molecule homologous to CXADR, FLJ22415 and ESAM. Int J Oncol 2003; 23: 525-31. (PMID: 12851705)
28. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32. (PMID: 12445278)
29. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-203. (PMID: 11027314)
30. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 70-7. (PMID: 12504661)
31. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ. Characterization of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Comm 1997; 236: 682-6. (PMID: 9245713)
32. Joosten CE, Cohen LS, Ritter G, Batt CA, Shuler ML. Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines. Biotechnol Prog 2004; 20: 1273-9. (PMID: 15296462)
33. Palmeri D, van Zante A, Huang CC, Hemmerich S, Rosen SD. Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells. J Biol Chem 2000; 275: 19139-45. (PMID: 10779521)
34. Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, Viars CS, Czekay S, Arden KC, Heath JK. Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem 2002; 277: 34531-9. (PMID: 12114523)
35. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7. (PMID: 11948459)
36. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38: 1133-40. (PMID: 12008203)
37. Baldus SE, Zirbes TK, Engel S, Hanisch FG, Monig SP, Lorenzen J, Glossmann J, Fromm S, Thiele J, Pichlmaier H, Dienes HP. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer 1998; 79: 133-8. (PMID: 9583726)
38. Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y. Tumor growth suppression by a mouse/ human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res 1998; 18: 17-24. (PMID: 9568050)
39. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18: 2282-92. (PMID: 10829049)
40. Martin IG, Cutts SG, Birbeck K, Gray S, Quirke P. Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? J Clin Pathol 1999; 52: 701-4. (PMID: 10655996)
41. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, Lawniczak M, Kolodziej B, Zyluk A, Stern PL. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol 1998; 10: 479-84. (PMID: 9855063)
42. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. Highdose therapy with 90Yttriumlabeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000; 6: 3095-102. (PMID: 10955789)
43. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, Reindl L, Muller-Hermelink HK. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 1998; 5: 549-52. (PMID: 9538151)
44. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multiinstitutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 2000; 6: 78-81. (PMID: 11069223)
45. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ, Old LJ. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000; 83: 493-7. (PMID: 10945497)